Taysha Gene [TSHA] vs Capricor [CAPR] Detailed Stock Comparison

Taysha Gene Therapies Inc.

NASDAQ
Loading...

Capricor Therapeutics Inc.

NASDAQ
Loading...

TLDR: Quick Comparison Summary

Based on 18 vital metrics comparison: Taysha Gene Therapies Inc. wins in 5 metrics, Capricor Therapeutics Inc. wins in 10 metrics, with 1 ties. Capricor Therapeutics Inc. appears stronger overall.

View Metrics Details

Vital Metrics Comparison

Metric Taysha Gene Therapies Inc. Capricor Therapeutics Inc. Better
P/E Ratio (TTM) 2.53 -15.61 Taysha Gene Therapies Inc.
Price-to-Book Ratio 7.39 6.62 Capricor Therapeutics Inc.
Debt-to-Equity Ratio 28.41 4.75 Capricor Therapeutics Inc.
PEG Ratio -15.71 -0.05 Capricor Therapeutics Inc.
EV/EBITDA -14.53 -16.23 Taysha Gene Therapies Inc.
Profit Margin (TTM) 0.00% 0.00% Tie
Operating Margin (TTM) -515.95% 0.00% Capricor Therapeutics Inc.
Return on Equity -68.45% -46.56% Capricor Therapeutics Inc.
Return on Assets (TTM) -27.42% -25.68% Capricor Therapeutics Inc.
Free Cash Flow (TTM) $-93.83M $-81.54M Capricor Therapeutics Inc.
1-Year Return 116.61% 202.93% Capricor Therapeutics Inc.
Price-to-Sales Ratio (TTM) 188.17 N/A N/A
Enterprise Value $1.59B $1.72B Capricor Therapeutics Inc.
EV/Revenue Ratio 162.58 N/A N/A
Revenue per Share (TTM) $0 $0 Taysha Gene Therapies Inc.
Earnings per Share (Diluted) $-0.34 $-2.26 Taysha Gene Therapies Inc.
Beta (Stock Volatility) 1.08 0.48 Capricor Therapeutics Inc.
Short % of Float 13.79% 19.17% Taysha Gene Therapies Inc.

Taysha Gene Therapies Inc. vs Capricor Therapeutics Inc. Stock Performance Analysis

Loading Price Chart...

TSHA
CAPR

Performance Comparison

Short-term Returns

Stock1D1W1M3M6MYTD
Taysha Gene Therapies Inc.-2.46%1.79%-14.31%25.61%40.15%8.38%
Capricor Therapeutics Inc.1.21%-6.88%-18.39%1.79%329.87%-3.43%

Long-term Returns

Stock1Y3Y5Y10Y15Y20Y
Taysha Gene Therapies Inc.116.61%643.04%-73.70%-76.01%-76.01%-76.01%
Capricor Therapeutics Inc.202.93%558.46%676.17%-7.24%-90.64%-97.72%

Performance & Financial Health Analysis: Taysha Gene Therapies Inc. vs Capricor Therapeutics Inc.

MetricTSHACAPR
Market Information
Market Cap i$1.84B$2.04B
Market Cap CategorySmall capMid cap
10 Day Avg. Volume i3,639,200987,380
90 Day Avg. Volume i3,156,5531,234,213
Last Close$5.55$27.67
52 Week Range$2.25 - $7.30$4.30 - $40.37
% from 52W High-23.97%-31.46%
All-Time High$33.35 (Jan 18, 2021)$3,500.00 (Oct 22, 2007)
% from All-Time High-83.36%-99.21%
Growth Metrics
Quarterly Revenue Growth1.71%N/A
Quarterly Earnings Growth1.71%-1.00%
Financial Health
Profit Margin (TTM) i0.00%0.00%
Operating Margin (TTM) i-5.16%0.00%
Return on Equity (TTM) i-0.68%-0.47%
Debt to Equity (MRQ) i28.414.75
Cash & Liquidity
Book Value per Share (MRQ)$0.87$5.33
Cash per Share (MRQ)$1.11$5.53
Operating Cash Flow (TTM) i$-93,090,000$-69,811,264
Levered Free Cash Flow (TTM) i$-56,697,624$-39,600,748
Dividends
Last 12-Month Dividend Yield iN/AN/A
Last 12-Month Dividend iN/AN/A

Valuation & Enterprise Metrics Analysis: Taysha Gene Therapies Inc. vs Capricor Therapeutics Inc.

MetricTSHA (Apr 26, 2026)CAPR (Apr 26, 2026)
Price Ratios
P/E Ratio (TTM) i2.53-15.61
Forward P/E i-15.71-56.73
PEG Ratio i-15.71-0.05
Price to Sales (TTM) i188.17N/A
Price to Book (MRQ) i7.396.62
Market Capitalization
Market Capitalization i$1.84B$2.04B
Enterprise Value i$1.59B$1.72B
Enterprise Value Metrics
Enterprise to Revenue i162.58N/A
Enterprise to EBITDA i-14.53-16.23
Risk & Other Metrics
Beta i1.080.48
Book Value per Share (MRQ) i$0.87$5.33

Financial Statements Comparison: Taysha Gene Therapies Inc. vs Capricor Therapeutics Inc.

Financial Metrics

Loading Financial Charts...

Revenue

Operating Margin

Profit Margin

Long Term Debt

Income Flow Analysis

Financial Statements Comparison

Income Statement

MetricTSHA (2025)CAPR (2025)
Revenue/Sales i9.77M0
Cost of Goods Sold iN/AN/A
COGS % of Revenue i0.0%-
Gross Profit iN/AN/A
Gross Margin i0.0%-
Research & Development i86.40M84.45M
Operating Income (EBIT) i-110.50M-108.14M
Operating Margin i-1,130.6%-
EBITDA i-106.59M-106.21M
EBITDA Margin i-1,090.6%-
Pre-Tax Income i-109.00M-105.04M
Pre-Tax Income % of Revenue i-1,115.3%-
Income Tax iN/A1,600
Income Tax % of Revenue i0.0%-
Net Income (Profit) i-109.00M-105.04M
Profit Margin i-1,115.3%-

Balance Sheet & Liquidity Metrics

MetricTSHA (2025)CAPR (2025)
Cash & Equivalents i319.77M287.85M
Total Current Assets i324.65M322.94M
Total Current Assets % of Revenue i3,321.9%-
Total Current Liabilities i26.55M35.84M
Total Current Liabilities % of Revenue i271.7%-
Long-Term Debt i68.28M14.32M
Long-Term Debt % of Revenue i698.6%-
Total Shareholders Equity i246.94M305.79M
Retained Earnings i-711.30M-304.88M
Retained Earnings % of Revenue i-7,278.2%-
Property, Plant & Equipment i12.75M22.27M

Cash Flow Statement Comparison

MetricTSHA (2025)CAPR (2025)
Operating Cash Flow i-98.84M-71.86M
Operating Cash Flow % of Revenue i-1,011.4%-
Capital Expenditures i-738,000-11.72M
Free Cash Flow i-93.83M-81.54M
FCF Margin i-960.1%-
Debt Repayment i-40.61MN/A
Common Stock Repurchase iN/AN/A

Short Interest & Institutional Ownership Analysis

MetricTSHACAPR
Shares Short i38.92M10.04M
Short Ratio i12.837.73
Short % of Float i13.79%19.17%
Shares Outstanding i285.05M57.37M
Float Shares i198.47M48.61M
% Held by Insiders i10.62%9.47%
% Held by Institutions i94.27%53.91%
% Held by Public i-4.89%36.62%

Dividend Analysis & Yield Comparison: Taysha Gene Therapies Inc. vs Capricor Therapeutics Inc.

MetricTSHACAPR
Last 12-Month Dividend iN/AN/A
Last 12-Month Dividend Yield iN/AN/A
3-Year Avg Annual Dividend iN/AN/A
3-Year Avg Dividend Yield iN/AN/A
3-Year Total Dividends iN/AN/A
Ex-Dividend DateN/AN/A